These findings in MSI ECs are not consistent with previous reports on CRCs because, in CRCs, PRSS56 appeared to promote tumor progression.[57] However, the high immunogenicity of the cancer-testis antigen may explain part of this discrepancy. The gene discussed is PRSS56; the disease is neoplasm.